Skip to content

Released Aug 8, 2023, after the close

10-Q filed Aug 8, 2023, 39 days after period end · 0000950170-23-039884

Q2 2023 · 10-Q
Revenue$187.02M+58.4% vs Q2 2022+6.7% vs Q1 2023
Net Income-$39.43MN/M vs Q2 2022N/M vs Q1 2023
EPS Diluted-$1.07N/M vs Q2 2022N/M vs Q1 2023
Gross Profit$119,551,000+38.3%
Operating Income-$36,632,000N/M
Operating Cash Flowderived-$5,516,000N/M
Free Cash Flowderived-$17,867,000N/M
Margins · derived
Gross margin63.9%−9.3 pt vs Q2 2022
Operating margin-19.6%−25.2 pt vs Q2 2022
Net margin-21.1%−23.2 pt vs Q2 2022

What the release said

The release

Same quarter

MetricQ2 2023Q2 2022Q2 2021Q2 2020
Revenue$187.02M$118.07M$121.39M$73.14M
Net Income-$39.43M$2.49M$2.42M-$18.42M
EPS Diluted-$1.07$0.12$0.12-$0.96

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Orthofix Medical Inc. · CIK 884624 · Engraved from SEC EDGAR